Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 6/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL7652927 | 0.88 | MAPK14 (0.50) | DHODHCTSKADORA3ADORA2AADORA1 | |
| Dimethylamine SCHEMBL7649217 | 0.87 | ALDH1A1 (0.45) | RIPK1MAPTRXFP1ADORA2AADORA1 | |
| Dimethylamine SCHEMBL7652894 | 0.85 | ALDH1A1 (0.48) | ADORA3ROCK2ADORA2AADORA1POLB | |
| SCHEMBL7652478 | 0.81 | CTSK (0.48) | DHODHRIPK1CTSKADORA3ROCK2 | |
| SCHEMBL7650966 | 0.80 | ADORA3 (0.45) | DHODHRIPK1CTSKADORA3MAPT | |
| Dimethylamine SCHEMBL7653735 | 0.79 | ALDH1A1 (0.44) | DHODH | |
| Dimethylamine SCHEMBL7679157 | 0.77 | ALDH1A1 (0.48) | MAPTPOLB | |
| Dimethylamine SCHEMBL7656109 | 0.76 | OPRM1 (0.38) | DHODHADORA3ADORA2AADORA1 | |
| Dimethylamine SCHEMBL7658435 | 0.76 | ALDH1A1 (0.44) | DHODHMAPTPOLB | |
| Dimethylamine SCHEMBL7655386 | 0.75 | ADORA2B (0.43) | ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492407-B2 | NEUROPROTECTIVE ACTIVITY | BOEHRINGER IMGELHEIM PHARMA KG (DE) | 2002-12-10 | — | — | US | claimed |
| US-20020045651-A1 | Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-18 | — | — | US | claimed |
| US-6492407-B2 | NEUROPROTECTIVE ACTIVITY | BOEHRINGER IMGELHEIM PHARMA KG (DE) | 2002-12-10 | — | — | US | disclosed |
| US-20020045651-A1 | Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045651-A1 | Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones | PARK7, IAPP, HIF1AN | DHODH 3668/4885RIPK1 433/4885CTSK 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.